Sifrol er indiceret til symptomatisk behandling af moderat til svær idiopatisk Restless Legs Syndrome i doser optil 0, 54 mg base (0, 75 mg salt) (se pkt.
Nausea and fatigue were more often reported in female patients treated with SIFROL (20.8% and 10.5%, respectively) compared to males (6.7% and 7.3%, respectively).